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 CURRENTOPINION Outpatient management of community-acquired
pneumonia
Filipe Froesa, Joa˜o Gonc¸alves Pereirab,c, and Pedro Po´voac,d,e
Purpose of review
Although most patients with community-acquired pneumonia (CAP) are treated as outpatients, the majority
of data regarding CAP management is provided by hospitals, either from emergency department or
inpatients. This was already noted in the first CAP guidelines, published in 1993, and the challenges
regarding the outpatient management of CAP persist nowadays. These include the uncertainty of the initial
diagnosis and risk stratification, the empirical choice of antibiotics, the overgrowing of antibiotic resistance
bacteria and the relative scarcity of novel antibiotics.
Recent findings
New molecular biology methods have changed the etiologic perspective of CAP, unveiling the role of virus.
Diagnostic uncertainty may lead to antibiotic overuse and bacteria resistance. Novel antibiotics along with
diagnostic improvement, related to the use of lung ultrasound and point-of-care biomarkers testing, may
help to improve CAP treatment. Prevention, especially the use of antipneumococcal vaccine, is instrumental
in reducing the burden of disease.
Summary
Most of CAP cases are managed in the outpatient setting. However, most research is focused on
hospitalized severe patients. New and awaited advances might contribute to aid diagnosis, cause and
assessment of patients with CAP in the community. This knowledge might prove decisive in improving
outcomes, as well as to the execution of stewardship programs that maintain current antibiotics, safeguard
future ones and reinforce prevention.
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INTRODUCTION
In 2018, the first published international guidelines
assessing community-acquired pneumonia (CAP)
celebrate its 25 years [1]. This document, published
in 1993 by the American Thoracic Society (ATS), was
at the same time pioneer and visionary, and deeply
changed the management of CAP.
CAP is a frequent entity and itshistory follows the
history of humankind. In 1881, Pasteur [2] and Stern-
berg [3] independently described a microorganism,
named Pneumococcus by Fraenkel because it caused
pulmonary disease [4]. Two decades later, William
Osler identified the clinical entity of pneumonia as
the ‘Captain of the men of death’ [5]. The introduc-
tion of serum therapy, and particularly vaccines and
antibiotics, had a major impact in the treatment and
prevention of pneumonia during the 20th century.
However, in the last 50–60years, no significantnovel
treatment has been introduced. Simultaneously new
pathogens are increasingly described (e.g. SARS,
MERS-CoV) and multidrug-resistant pathogens are
a cause of concern. As a result, pneumonia remains
a major public health problem, with enormous mor-
bidity and mortality [6].
Despite many advances, some challenges persist
since 1993. These include the difficulty in establish-
ing the initial clinical diagnosis, risk stratification,
empirical choice of antibiotics, the relative scarcity
of novel antibiotics and the importance of knowing
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local microbiological susceptibility patterns. The
uncertainty in CAP diagnosis also leads to antibiotic
overuse and growing bacteria resistance.
It is expected that the next Infectious Disease
Society of America (IDSA)/ATS guidelines actuali-
zation due in 2019, will clarify some of these chal-
lenges [7
&
].
EPIDEMIOLOGY
Respiratory tract infections (RTI) remain the most
common infectious disease in the ambulatory set-
ting [8]. Calculating the true incidence of CAP,
however, remains a challenge. Patients with mild
systemic and respiratory symptoms rarely seek their
general practitioners; this is evident in incidence
studies from France with less than seven CAP per
year per family physician [9]. The use of confirma-
tory diagnostic tests varies widely, namely for the
availability of chest X-ray and point-of-care testing
(POCT). With these limitations, the estimated
annual incidence of CAP is 5–11 cases per 1000
adults [10]. CAP incidence presents a marked sea-
sonal variation (more in winter), a U-shaped age
distribution (more frequent in children and the
elderly), a sex asymmetry (more in men) and is
more frequent in the presence of known risk factors
(alcohol, tobacco consumption, chronic pulmonary
disease, renal failure and malnutrition) or medica-
tions (inhaled corticosteroids, proton pump inhib-
itors, antipsychotic drugs, oral antidiabetic drugs,
namely DPP-4 inhibitors) [11
&
,12
&
].
The percentage of CAP patients admitted to
hospital varies from country to country ranging
between 1.1 and 4.0 per 1000 inhabitants [13]. This
means that roughly two-thirds of patients are
treated as outpatients. The annual incidence of hos-
pitalized CAP seems to have decreased slightly in the
United States (2.67 to 2.48/1000 inhabitants/year in
2000 and 2010–2012) [14,15], whereas it is increas-
ing in several European countries, such as the UK
(1.48–1.98/1000 inhabitants/year between 1997–
1998 and 2004–2005) [13], Germany (2.75–2.96/
1000 inhabitants/year in 2005 and 2006) [16]
and Portugal (3.02–4.70/1000 inhabitants/year
in 2000 and 2009) [17]. These differences could
reflect different studied populations and healthcare
organizations.
A global study found that lower RTI, including
pneumonia, ranks fifth as the most common cause
of death worldwide, behind Alzheimer disease and
other dementias, and shows a slight decrease to
36.8/100000 inhabitants [18]. But even in higher
income countries, pneumonia remains the leading
cause of death by infectious diseases [7
&
] and ranks
eighth amongst the causes of death in the United
States in 2014 [19].
The decrease in hospital admissions and CAP
mortality observed in some countries [20,21]may be
the result of widespread immunization of high-risk
groups with pneumococcal and influenza vaccines
together with improvement of care process [7
&
].
CAUSE
Although more than 100 microorganisms can cause
CAP, a limited number account for the majority of
cases. Nowadays, the use of molecular diagnostic
techniques can yield a microbiological diagnosis in
75% of cases [22]; however, outside research set-
tings, this figure drops to 10–20% [23].
In a review of 46 European outpatient studies
[24], there was microbiological isolation in half the
patients. Pneumococcus was the most common
organism accounting for 38% of isolates. The pneu-
mococcal incidence is higher in countries with
lower use of pneumococcal vaccines and higher
tobacco use [25]. In Norway, a study of 267 inpa-
tients [26], isolated an aetiological agent in 63% of
cases,mostly pneumococcus (30%), influenza (15%)
and rhinovirus (12%). Viral–bacterial co-detections
were established in one-third of patients. In another
US study, cause was established in 38% of 2320
patients, particularly rhinovirus (9%), influenza
virus (6%) and pneumococcus (5%) [14]. Despite
the frequent identification of viruses, their role as
colonizers, predisposing to secondary bacterial
infection or as microorganisms responsible for
pneumonia is not well established, particularly for
noninfluenza viruses.
KEY POINTS
 The majority of patients with CAP are treated as
outpatients, although most of the research on CAP
originates from inpatients.
 The main challenges in the outpatient management of
CAP persist. These include the initial clinical diagnosis,
its risk stratification and the empirical choice of
antibiotics.
 Despite the growing acknowledgment of viral agents,
all patients with CAP should receive antibiotic
treatment. These should be adapted from current
guidelines and must take into account local
microbiological susceptibility patterns.
 The worrying problem of antibiotic resistance increases
the need for stewardship programs along with
improvements in diagnostic accuracy, which maintains
current antibiotics, safeguards future ones and
reinforces prevention.
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In the previously mentioned review [24],
community-managed CAP was attributed to atypi-
cal microorganisms in 30% of patients. In a study
from fourDutchhospitals, atypicalmicroorganisms
were isolated in 20.7% of patients [27]. Risk factors
for atypical agents were: noninfluenza season,
age less than 60 years, male sex and absence of
COPD.
CAP because of Legionella spp. is more frequent
in specific geographic locations. Since 2014, several
Legionella outbreaks have been reported [28–31]. In
the second largest outbreak in the world, with 430
cases, occurred the first documented case of proba-
ble person-to-person transmission of Legionnaires’
disease [32
&
].
DIAGNOSIS AND RISK STRATIFICATION
The definite diagnosis of pneumonia requires sys-
temic manifestations, signs and symptoms of lower
RTI, a new or progressive pulmonary infiltrate in
chest X-ray and, finally, microbiologic documenta-
tion. However, even in severe CAP, microbiologic
documentation is obtained in only 50% of patients.
Radiologic evaluation is rarely available in the
primary care setting; hence, family physicians fre-
quently will rely solely on clinical evaluation for
CAP diagnosis. Clinical criteria are overly sensitive
and poorly specific and, if used indiscriminately,
could result in antibiotics overuse.
Older patients, however, often present with
atypical symptoms, such as falls, fatigue, lethargy,
delirium, anorexia [33]. This is particularly worrying
as the elderly are at higher risk of resistant micro-
organisms and death [34].
Several scoring systems have been developed to
stratify severity of pneumonia like the PSI, CURB-65,
IDSA/ATS 2007, SMART-COP, SCAP. Although these
severity scores performed well in the identification
of high-risk patients, they have not been designed
to be applied to outpatients. There are three scores
that do not require laboratory testing. The NEWS
(National Early Warning Score) includes seven
items: respiratory rate, peripheral oxygen satura-
tion, oxygen supplementation, temperature, SBP,
heart rate and level of consciousness. It has a mod-
erate association with mortality but performed bet-
ter than PSI and CURB-65 to identify patients
needing ICU admission [35]. The other two scores
are even simpler and both use the same three clinical
items: level of consciousness, respiratory rate and
blood pressure. One is an ‘old’ CAP score, the CRB/
CRB-65 [36,37], the other is a data-driven score
using big data, the qSOFA [38,39]. The performance
of qSOFA for mortality prediction was similar to
CRB, but better for ICU admission.
In the near future, POCT will become more
available in the primary care setting [40]. Currently,
POCT exists for several laboratory variables, such as
CRP and PCT, but the array of possibilities is wide
and could include microbiologic identification. The
challenge is how to use this technology and its
additional information. Currently, there are three
RCTs performed in primary care settings using a
biomarker decision tree algorithm in patients with
suspicion of lower RTI [41–43]. In two RCTs, both
with less than 500 patients, one using PCT and the
other CRP, the authors found a significant decrease
in antibiotic prescription without any adverse
events. In a Cochrane review published in 2014,
CPR in primary care can reduce antibiotic use; how-
ever, with a possible increase in hospitalizations
[44]. The larger RCT (N¼1656) that evaluated a
PCT-guided use of antibiotics for suspected lower
RTI, was performed in 14 US hospitals with a high
adherence to quality measures. The study showed
no impact on the rate of antibiotic prescription and
consumption [45
&
].
The combination of a severity scoring system
and a biomarker has also been tested. The additional
value of CRP combined with PSI and CURB-65 was
evaluated but produced conflicting results [46,47].
Probably, more important that any single value of
CRP would be its kinetics after 12–24h, which could
contribute to the clinical decision-making process
[48]. Other biomarkers, like PCT and proadrenome-
dulin, have also been tested with similar results
[49,50].
Lack of chest imaging in the primary care setting
is a major limitation in pneumonia diagnosis. The
development of portable ultrasound devices and
training of primary care physicians could change
the paradigm of pneumonia diagnosis [51].
TREATMENT
Antibiotic treatment is recommended for all
patients with CAP, including outpatients
[1,10,52–56]. Treatment success relies on prompt
delivery of antibiotics, adapted to the likely causa-
tive organisms and clinical severity. Antibiotic selec-
tion should take into consideration up-to-date local
guidelines adapted to the microorganism preva-
lence and susceptibility pattern (Table 1). The anti-
biotic management of CAP was the subject of a
recently published comprehensive review [57
&
].
Proposed first-line therapy in the outpatient
includes monotherapy with a b-lactam, a macrolide
or a tetracycline. These choices exclude those with
significant comorbidities or at risk of antibiotic
resistance. Fluoroquinolone use is ubiquitous
but, from an antibiotic stewardship perspective, a
Outpatient management of CAP Froes et al.
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Table 1. Guidelines for outpatient treatment of CAP in several countries between 1993 and 2018
Organization
(country) ATS (US) [1] IDSA/ATS (US) [53] NICE (UK) [60]
Chinese Thoracic Society,
Chinese Medical
Association (China) [53]
South African Thoracic Society,
Federation of Infectious Diseases
Societies of Southern Africa [54]
Brazilian Thoracic
Association
(Brazil) [56]
Year 1993 2007 2014 2016 2017 2018
Outpatient
treatment
60 years or less of
age AND without
comorbidity:
Macrolide
OR
Tetracycline
At least 60 years of
age AND/OR
comorbidity:
second-generation
cephalosporin
OR
TMP/SMX
OR
Beta-Iactam/beta-
Iactamase
inhibitor

Macrolide
Previously healthy and
no risk factors for
DRSP infection:
Macrolide
OR
Doxycycline
Presence of
comorbidities (e.g.
chronic heart, lung,
liver, or renal
disease; diabetes
mellitus; alcoholism;
malignancies;
asplenia;
immunosuppressing
conditions or use of
immunosuppressing
drugs); use of
antimicrobials within
the previous 3
months; or other risks
for DRSP infection:
Fluoroquinolone
OR
b-lactam and macrolide
(doxycycline is an
alternative to the
macrolide)
Amoxicillin.
Macrolide or
tetracycline for
patients allergic
to penicillin.
Young adults without
underlying disease (s):
Aminopenicillins, penicillins-b–
lactamase inhibitor;
First or second generation
cephalosporins;
Doxycycline or minocycline
(suspected Mycoplasmaor
Chlamydia infection);
fluoroquinolone (in regions
with higher resistance rates
to macrolides or in patients
hypersensitive or intolerant
to the drugs mentioned
above); macrolides (only in
regions with lower
resistance rates).
Patients with underlying
disease(s) or elderly patients
(age >65 years):
Penicillins-b-lactamase inhib.;
Second or third generation
cephalosporin.;
fluoroquinolones; Penicillins-
b-lactamase inhibitor or
Second or third generation
cephalosporins plus
doxycycline or minocycline
or macrolides
<65 years old, without antibiotic
exposure in the past 90 days or
comorbidities: amoxicillin
(macrolide in the presence of
severe b-lactam allergy)
65 years old, have received
antibiotics within the previous
90 days, or who have
comorbidities:
Amoxicillin-clavulanate OR
second generation cephalosporin
No comorbidities, no
recent use of antibiotics,
no risk factors for
resistance, and no
contraindication or
history of allergy:
b–lactam
OR
Macrolide
Use of antimicrobials
within the previous 3
months, regions where
the rate of resistance to
macrolides is >25%,
concomitant diseases
(COPD, liver or kidney
disease, cancer,
diabetes, congestive
heart failure, alcoholism,
or immunosuppression):
Macrolide combined with
b-lactam
OR
Fluoroquinolone
ATS, American Thoracic Society; COPD, Chronic obstructive pulmonary disease; DRSP, drug-resistant S. pneumoniae; IDSA, Infectious Diseases Society of America; NICE, The National Institute for Health and Care
Excellence; TMP/SMX, Trimethoprim/sulfamethoxazole.
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narrower coverage is preferable, particularly in
countries with high tuberculosis prevalence [54].
In a retrospective US analysis from 2011 to 2015,
and involving 251947 adult patients, the most
commonly prescribed antibiotics to outpatients
were macrolides (43.6%), fluoroquinolones (43%),
b-lactam compounds (6.5%) and tetracyclines
(5.5%) [58].
In the United Kingdom [10,59], atypical micro-
organism coverage is not routinely recommended.
However, both Mycoplasma pneumoniae and
Chlamydia pneumoniae can cause severe CAP, and
adequate antibiotic treatment even in mild disease
can reduce morbidity and symptom duration [60].
A recent Dutch study compared monotherapy
with a b-lactam, a fluoroquinolone or a combina-
tion of a b-lactam combined with a macrolide in
inpatients [61]. There was no significant difference
in 90-day mortality between the three groups. How-
ever, this study had several limitations. In 25% of
patients, there was no radiographic confirmation of
pneumonia, atypical organisms were identified in
only 2% of patients, 39% of patients randomized
to the monotherapy b-lactam group had atypical
coverage and 12% of patients to the b-lactam com-
bined with macrolide did not receive a macrolide
[7
&
,57
&
].
Antimicrobial resistance is a growing problem.
The current level of b-lactam pneumococcal resis-
tance in the community is not generally associated
with treatment failure when appropriate agents (e.g.
amoxicillin, ceftriaxone, cefotaxime) and adequate
doses are used [62]. The incidence of pneumococcal
and mycoplasma macrolide resistance reaches 55–
60% in China [53] and is nowmore than 25% across
the whole USA [63], which can limit its use as
monotherapy [64]. The use of clinical scores
may help identify patients infected with resistant
microorganisms [65], and lead to better antibiotic
accuracy.
Strategies to reduce the overuse of antibiotics in
outpatients, especially for acute RTI (easily mistaken
for CAP), are needed, as almost 50%of these patients
receive antibiotics [66
&
,67].
The development of new antibiotics is crucial
and new drugs will be available soon. For outpatient
management, the most promising seem to be oma-
dacycline and lefamulin (Table 2). Omadacycline
is a new, once-daily, intravenous and oral, broad-
spectrum antibiotic of the tetracycline family that
was approved by the Food and Drug Administration
(FDA) in October 2018 for the treatment of bacterial
CAP. Omadacycline will probably be available
in 2019. Also, in 2018, the results of Lefamulin
Evaluation Against Pneumonia (LEAP 2) study
were presented, showing noninferiority of a 5-day
oral lefamulin treatment compared with a standard
7-day oral moxifloxacin treatment [68].
REASSESSMENT
Effective clinical response to therapy is commonly
defined as resolution of fever, normalization of
heart and respiratory rate, normal blood pressure
and normal oxygen saturation [53]. Among outpa-
tients, treatment failure is usually defined as the
need for hospitalization or change in antibiotic
therapy.
Table 2. Antibiotics being developed with possible use for outpatient management of community-acquired pneumonia
Antibiotic Class Spectrum of activity Route Comments
Omadacycline Tetracycline DRSP, atypicals, Staphylococcus
aureus (including MRSA), some
Gram-negatives and bacteria
resistant to older tetracyclines,
like doxycycline
Oral and
intravenous
Approved by the FDA in
October 2018 for the treatment
of acute bacterial skin and skin
structure infections and community-
acquired bacterial pneumonia
Lefamulin Pleuromutilin DRSP, atypicals, S. aureus (including
MRSA), some Gram-negatives
Oral and
intravenous
In Lefamulin Evaluation Against
Pneumonia (LEAP 2) study
presented in October 2018, 5-day
oral lefamulin demonstrated
noninferiority for both FDA and
EMA efficacy endpoints versus 7-
day oral moxifloxacin
Solithromycin Ketolide
(fourth
generation
macrolide)
DRSP (including macrolide-resistant),
atypicals (including macrolide-
resistant Mycoplasma
pneumoniae), Moraxella
catarrhalis, S. aureus (including
community-acquired MRSA)
Oral and
intravenous
No developments since December
2016, after FDA request for further
safety investigations
DRSP, drug-resistant Streptococcus pneumoniae; EMA, European Medicines Agency; FDA, Food and Drug Administration; MRSA, methicillin-resistant S. aureus.
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Therapeutic failure in outpatients seems to be
unusual, ranging from 2.3–8% [69–71]. Moreover,
mortality is low, less than 2.5% [70], both in patients
discharged from the emergency department [69,72]
or assessed in the primary care setting. Yet a note of
caution is warranted, as mortality in the small group
of patients who has late hospital admission may be
high [72].
NICE guidelines [59] recommend that low-
severity CAP patients be advised to seek further
medical consultation if their symptoms do not
begin to improve in a short period of time or if they
feel that their condition is deteriorating. This
approach seems to be quite intuitive, although there
is scarce data to support it. A clinical reevaluation,
either in person or by phone, may be a useful
approach.
Recommendations should be provided for the
ambulatory patient. Treatment failure may also be
associated with increased costs. In a large cohort
(N¼9446) from the United States, authors identi-
fied a 58% increase in costs when treatment failure
occurred, with either antibiotic retreatment (89.4%)
or hospitalization (10.6%) [73].
Follow-up chest X-ray has been recommended,
especially for patients at increased risk of underlying
neoplastic disease [74]. Delay in the complete reso-
lution of chest infiltrates is common, especially in
patients who are aged at least 50 years or with
multiple comorbidities [55].
An increase in cardiovascular disease risk after
an episode of CAP is increasingly recognized [75
&
].
It is not known if outpatients with less severe CAP
share the same risk.
PREVENTION
In 2015, the results of the CAPITA trial lead to a
significant increase in recommendations for immu-
nization in adults [76]. In the United States, the
Advisory Committee on Immunization Practices
(ACIP) recommends that all adults aged at least
65 years have the 13-valent pneumococcal conju-
gate vaccine (PCV13) [77] and at least 1 year later
the 23-valent pneumococcal polysaccharide vaccine
(PPSV23) [78]. Yet, the uptake of PCV13 in the
United States is low among adults aged 65 and older.
Centers for Disease Control and Prevention (CDC)
researchers found that by 2016, 43% of beneficiaries
had received at least one dose of PPSV23, 32% one
dose of PCV13 and 18% had received both. The
highest vaccination cover was seen among patients
who were older, white, or had chronic medical
conditions [79]. A review of ACIP recommendations
is due on 2019.
In other developed countries, pneumococcal
vaccination is widely recommended. France now
recommends the scheme PCV13->PPSV23 to all
immunocompromised or immunocompetent adults
at risk because of a predisposing condition for pneu-
mococcal disease [80]. Both South Africa 2017 and
South Korea 2018 CAP guidelines recommend pneu-
mococcal and influenza vaccination as a key pillar of
antibiotic stewardship [54,55].
In a real-world study with 2034 CAP inpatients,
aged at least 65 years, the PCV13 showed an adjusted
effectiveness of 71.1–73.3% for prevention of CAP
caused by the vaccine serotypes [81
&
]. Several studies
[11
&
,82] investigated the association between CAP
and lifestyle factors. The association lead to a bundle
of lifestyle interventions that include responsible
alcohol consumption, smoking cessation, dental
hygiene, dietary advice to ensure good nutritional
status, the avoidance of children with lower RTI and
vaccination against influenza and pneumococcus
[82,83].
CONCLUSION
Even though most patients with CAP are treated in
the community, the majority of research comes
from inpatients. Since the publication of CAP guide-
lines in 1993 the main challenges persist. These
include the difficulty in establishing the initial diag-
nosis, its risk stratification, the empirical choice of
antibiotics and the importance of localmicrobiolog-
ical susceptibility patterns. New molecular biology
methods have changed the etiologic perspective of
CAP, particularly the role of viruses. These methods,
along with lung ultrasound and biomarkers might
improve diagnosis accuracy and severity stratifica-
tion. Antibiotic resistance is a growing problem that
reinforces the importance of novel antibiotics and
disease prevention.
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